Biosig technologies, inc. (BSGM)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-12,763

-

-

-

-5,869

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-5,766

-2,637

-4,544

-1,800

-3,078

-3,272

-1,374

-1,537

-6,092

-2,582

-2,024

377

-4,761

-3,052

-2,608

-3,960

-787

-1,117

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization

21

17

18

9

7

3

2

2

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity based compensation

4,412

7,481

1,969

3,057

2,670

2,257

397

3,556

388

3,609

56

522

560

546

311

4,022

1,119

1,060

1,566

3,706

1,634

1,781

3,405

212

343

Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC

3,174

-

-

-

0

-

-

-

-

0

0

0

543

0

0

0

0

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

2

2

2

3

2

2

2

2

2

2

2

2

3

3

4

4

Changes in operating assets and liabilities:
Inventory

222

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Vendor deposits

100

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

10

-6

-61

180

-21

32

-19

47

2

-33

-24

13

27

-0

-7

130

-20

-52

-98

115

-8

-24

-6

17

3

Payment of long term deposit

-

-

-

-

-

7

-2

-36

-5

2

8

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-455

764

-218

345

-354

489

243

-119

-134

-827

59

660

209

-52

155

42

4

-119

73

-54

-233

111

-43

-58

-119

Lease liability, net

1

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

-

-

-

0

14

190

388

Lease liability, net

-

-

-

-

-

-

0

0

0

530

113

-60

-373

384

17

-556

-268

63

2,851

198

0

-

-

-

-

Stock based payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-132

-513

419

226

0

0

0

Deferred rent payable

-

-

-

-

-

-1

-0

-0

-0

0

0

0

0

0

0

-0

-0

-0

-2

0

0

0

0

0

1

Net cash used in operating activities

-5,942

-3,901

-3,939

-4,119

-3,522

-2,969

-2,489

-2,410

-2,387

-2,254

-1,762

-1,843

-1,609

-1,262

-1,078

-1,598

-1,167

-1,092

-862

-1,349

-1,219

-461

-573

-456

-505

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of patent costs

0

0

0

52

58

40

-30

258

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of trademark costs

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

20

93

38

30

14

16

13

4

3

2

5

0

1

4

6

5

0

6

0

6

2

0

3

0

0

Net cash used in investing activity

-20

-91

-38

-83

-73

-57

16

-262

-3

-2

-5

0

-1

-4

-6

-5

0

-6

0

-8

-2

0

-3

0

0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock

9,052

1,387

0

0

8,619

0

3,871

4,998

270

1,890

1,081

1,239

1,799

2,172

530

2,171

352

1,717

0

0

3,042

432

804

503

229

Proceeds from sale of Series E preferred stock

-

-

-

-

-

-

-

-

115

-249

39

239

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of Series E preferred stock

-

-

-

-

-

-

0

0

1,492

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

301

-

-

-

1,459

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of options

-

-

-

-

-

0

615

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net repayments of related party advances

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-0

-10

-20

Net cash provided by financing activities

9,353

3,792

5,952

3,603

10,079

197

6,079

5,310

1,878

3,570

1,121

1,479

1,799

2,172

530

2,171

352

1,717

0

495

3,042

432

804

493

208

Net increase in cash and cash equivalents

3,391

-

-

-

6,483

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

2,638

-512

1,313

-646

-363

188

905

-554

567

-815

618

-862

-862

1,819

-29

226

36

-296

Supplemental disclosures of cash flow information:
Cash paid during the period for interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

0

0

1

11

-9

7

1

Cash paid during the period for income taxes

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Noncash investing and financing activities:
Reclassify derivative liability to equity

-

-

-

-

-

0

0

0

3,044

-

-

-

-

-

-

-

-

-

-

-

5,440

-

-

-

-

Reclassify initial fair value of derivative and warrant liabilities from equity upon issuance of Series D preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Dividend payable on preferred stock charged to additional paid in capital

4

4

4

4

10

104

194

280

305

-

-

-

23

-

-

-

-

-

-

-

-

-

-

-

-

Right-to-use assets and lease liability recorded upon adoption of ASC 842

0

0

0

0

422

0

0

0

0

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Series C Preferred Stock [Member]
Common stock issued upon conversion preferred stock and accrued dividends

15

0

0

399

0

0

146

569

28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Embedded Derivative Financial Instruments, Upon Issuance of Series D Preferred Stock [Member]
Reclassify derivative liability to equity

-

-

-

-

-

-

-

278

262

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Upon Adoption of ASU 2017-11 [Member]
Reclassify derivative liability to equity

-

-

-

-

-

0

0

0

3,044

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-